Viatris, Kindeva Announce U.S. Court's Invalidation Of AstraZeneca's Symbicort Patent

Viatris Inc. (VTRS) Thursday announced that U.S. District Court has found AstraZeneca's Symbicort patent invalid for lack of written description and lack of enablement. According to Viatris and Kindeva Drug Delivery L.P. today's court decision marks the fourth Symbicort patent to be found either not infringed or invalid.

Viatris subsidiary Mylan Pharmaceuticals Inc. had received approval from FDA for its Abbreviated New Drug Application or ANDA for Breyna, the first approved generic version of AstraZeneca's Symbicort. Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease or COPD.

Viatris President Rajiv Malik said the District Court for the Northern District of West Virginia affirms Viatris' continuing efforts to break down barriers to patient access.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Societe Generale Group reported Wednesday a weak profit in its fourth quarter, despite higher net banking income. Further, the French Financial services major proposed a dividend and around 440 million euros share buyback program. The company also confirmed fiscal 2025 financial targets. City of Industry, California-based Titans Global Inc. is recalling certain JSJ branded cakes citing potential to contain undeclared eggs, a known allergen, the U.S. Food and Drug Administration said. The recall involves its 95g packages of JSJ Chocolate Cake, JSJ ZSR Cake, and JSJ DMC Leaf Cake food treats. Tech major Google, owned by Alphabet Inc., has unveiled a new chatbot tool called Bard. The experimental conversational artificial intelligence or AI service is built on a large language model, powered by the company's Language Model for Dialogue Applications or LaMDA.
Follow RTT